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Background: Improvement of transduction and augmentation of cytotoxicity are crucial for adenoviruses
(Ad)-mediated gene therapy for cancer. Down-regulated expression of type 5 Ad (Ad5) receptors on human
tumors hampered Ad-mediated transduction. Furthermore, a role of the p53 pathways in cytotoxicity mediated
by replication-competent Ad remained uncharacterized.
Methods: We constructed replication-competent Ad5 of which the E1 region genes were activated by a transcriptional
regulatory region of the midkine or the survivin gene, which is expressed preferentially in human tumors. We also
prepared replication-competent Ad5 which were regulated by the same region but had a fiber-knob region
derived from serotype 35 (AdF35). We examined the cytotoxicity of these Ad and a possible combinatory use of
the replication-competent AdF35 and Ad5 expressing the wild-type p53 gene (Ad5/p53) in esophageal carcinoma
cells. Expression levels of molecules involved in cell death, anti-tumor effects in vivo and production of viral
progenies were also investigated.
Results: Replication-competent AdF35 in general achieved greater cytotoxic effects to esophageal carcinoma
cells than the corresponding replication-competent Ad5. Infection with the AdF35 induced cleavages of caspases
and increased sub-G1 fractions, but did not activate the autophagy pathway. Transduction with Ad5/p53 in
combination with the replication-competent AdF35 further enhanced the cytotoxicity in a synergistic manner.
We also demonstrated the combinatory effects in an animal model. Transduction with Ad5/p53 however suppressed
production of replication-competent AdF35 progenies, but the combination augmented Ad5/p53-mediated p53
expression levels and the downstream pathways.
Conclusions: Combination of replication-competent AdF35 and Ad5/p53 achieved synergistic cytotoxicity due to
enhanced p53-mediated apoptotic pathways.
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Esophageal squamous cell carcinoma, which frequently
developed in aged persons, remains intractable despite a
recent progress in multi-modal treatments. Adenovi-
ruses (Ad)-mediated gene transfer is a possible strategy
to improve the prognosis by transducing the tumor cells* Correspondence: mtagawa@chiba-cc.jp
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which utilize the coxsackie adenovirus receptor (CAR)
molecules as one of the major cellular receptors, are com-
monly used as a gene transfer vector and Ad5-mediated
transduction is subjected to an expression level of CAR on
the target cells [1]. Expression of CAR, ubiquitously de-
tected in normal epithelia, is often down-regulated in
various types of human tumors including esophageal
carcinoma, which results in inefficient Ad5-mediated
transduction [2, 3]. In contrast, type 35 Ad (Ad35) use
CD46 molecules as a main cellular receptor andticle distributed under the terms of the Creative Commons Attribution
s/by/4.0), which permits unrestricted use, distribution, and reproduction in
roperly credited. The Creative Commons Public Domain Dedication waiver
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man tumors [4, 5]. Previous studies showed that chimeric
Ad5 vectors of which the fiber-knob portion was replaced
by that of Ad35 (AdF35) infected target cells with the
same efficacy as Ad35 [1, 6]. The AdF35 can thereby be a
vector to transduce low CAR-expressing cells which are
resistant to Ad5 infection. The differential receptor usage
has also an advantage in simultaneously transferring dual
genes into the same target cells. Ad5 infection down-
regulated CAR expression levels on target cells through
receptor internalization and hampered subsequent Ad5-
mediated transduction. AdF35-mediated transduction was
however not impaired by precedent Ad5 infection since
the down-regulated receptor expression was exclusive
each other [7].
Replication-competent Ad, designed to propagate spe-
cifically in tumors followed by spread of the viral pro-
genies into neighboring tumor cells, can overcome low
transduction efficacy and subsequently augment anti-
tumor effects [8]. We previously demonstrated that a
transcriptional regulatory region of the midkine (MK) or
the survivin (Sur) gene, expressed in a number of human
tumors but scarcely in normal tissues [9, 10], effectively
activated an exogenous gene preferentially in tumors
[11–13]. Moreover, we demonstrated that replication-
competent Ad5 of which the E1 genes were activated by
the MK regulatory region produced anti-tumor effects
on hepatocellular carcinoma [14].
Ad5 expressing the wild-type p53 gene (Ad5/p53) have
been clinically in use for cancer treatments and produced
combinatory anti-tumor effects with chemotherapeutic
agents [15, 16]. We also demonstrated that Ad5/p53
produced cytotoxic effects on human esophageal carcin-
oma and that the cytotoxicity was linked with CAR ex-
pression levels [17]. These results raise a possibility that
enhanced p53 expression in combination with replication-Table 1 Infectivity of Ad5 and AdF35 to esophageal carcinoma cells
Cells p53 status Mutated codon
TE-1 mutated Codon 272
TE-2 wild-type
TE-10 mutated Codon 242
TE-11 wild-type
YES-2 mutated Codon 236
YES-4 wild-type
YES-5 mutated Codon 280
YES-6 wild-type
T.Tn mutated Codon 214 and 258
HEK293
Cells were infected with Ad5/GFP or AdF35/GFP at a 30 MOI and were analyzed for
CAR expression levels were determined with flow cytometry and are expressed withcompetent Ad augments the anti-tumor effects. In this
study, we examined cytotoxicity of replication-competent
AdF35 powered by regulatory region of MK (AdF35-MK)
or Sur (AdF35-Sur) on a panel of human esophageal car-
cinoma cells and examined a possible combinatory effect
of Ad5/p53 and the AdF35.
Methods
Cells and mice
Human esophageal squamous cell carcinoma lines, TE-1,
TE-2, TE-10, TE-11, YES-2, YES-4, YES-5, YES-6 and
T.Tn cells, from Cell Resource Center for Biomedical
Research, Tohoku University, Sendai, Japan, were cul-
tured with RPMI 1640 medium supplemented with 10 %
fetal calf serum. The p53 genotype of respective tumors
is shown in Table 1. Human embryonic kidney (HEK)
293 cells and human lung carcinoma A549 cells, from
American Type Culture Collection (Manassas, VA,
USA), were cultured with DMEM medium supple-
mented with 10 % fetal calf serum. BALB/c nu/nu mice
(5-6 week-old females) were purchased from Japan SLC
(Hamamatsu, Japan).
Ad preparation
Replication-incompetent Ad5 DNA bearing the wild-
type p53, the green fluorescent protein (Ad5/GFP) and
the β-galactosidase gene (Ad5/LacZ) were constructed
by ligation of transgene-harboring pShuttle 2 (Takara,
Tokyo, Japan) and Adeno-X vector (Takara). Ad35 DNA
bearing the above transgenes (AdF35/GFP, AdF35/LacZ)
was produced with Adeno-X vector substituted with the
Ad35 fiber-knob region. The fiber-knob modified
Adeno-X DNA was created by replacing a fragment con-
taining the Ad35 fiber-knob region (Avior therapeutics,
Seattle, WA) (AY271307 at 30,827–33,609) with that of
Ad5-derived region. The replication-incompetent Adand CAR expression levels
CAR expression GFP-positive cells (%)
Ad5 AdF35
6.57 8.06 ± 1.17 53.47 ± 0.10
19.22 0.79 ± 0.14 10.15 ± 0.44
14.73 16.15 ± 0.52 35.33 ± 0.67
22.25 22.86 ± 0.53 42.82 ± 0.74
0.19 5.09 ± 1.29 51.54 ± 0.36
26.87 27.18 ± 0.16 61.23 ± 0.07
15.40 22.18 ± 0.32 69.97 ± 0.89
30.23 16.59 ± 0.25 27.63 ± 0.17
8.12 0.49 ± 1.00 21.60 ± 0.15
56.97 87.20 ± 0.52 78.05 ± 0.70
the fluorescence with flow cytometry. Averages and the SEs are shown (n = 3).
an arbitrary unit
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gene. Replication-competent Ad DNA of which the E1
genes were activated by a transcriptional regulatory re-
gion of the MK or the Sur gene (Ad5/MK, AdF35/MK,
Ad5/Sur, AdF35/Sur) were prepared with the regulatory
sequences-harboring pShuttle 2 and Adeno-X vector or
the fiber-knob replaced Adeno-X vector. The Ad DNA
was transfected into HEK293 cells and the Ad were puri-
fied with an Adeno-X purification kit (Takara).
Infectivity of Ad and receptor expression
Cells were infected with Ad5/GFP or AdF35/GFP at 30
multiplicity of infection (MOI) for 30 min and were
washed to remove the Ad. They were cultured for 2 days
and were analyzed for the fluorescence with FACSCali-
bur and CellQuest software (BD Biosciences, San Jose,
CA, USA). Cell populations that showed fluorescence
greater than the brightest 5 % of uninfected cells were
judged as positively stained. Cells were stained with anti-
CAR antibody (Ab) (Upstate, Charlottesville, VA, USA)
followed by fluorescein isothiocyanate-conjugated anti-
mouse IgG Ab, and were analyzed for their fluorescence
intensity with FACSCalibur and CellQuest software. The
mean fluorescence intensity of the stained cells was
expressed as an arbitrary FL1 unit.
Cell cycle analysis
Cells were fixed in 100 % ethanol, treated with RNase
(50 μg/ml) and stained with propidium iodide (50 μg/ml).
Cell cycle distributions were analyzed with FACSCalibur
and CellQuest software.
In vitro cytotoxicity assay and cell proliferation
Cells were seeded in 96-well plates (5x103/well), infected
with Ad at different amounts of virus particles (vp) and
were cultured for 5–6 days. Cell viability was determined
with a cell-counting WST kit (Wako, Osaka, Japan). The
amount of formazan produced in each well was deter-
mined with the absorbance at 450 nm and the relative
viability was calculated based on the absorbance without
any treatments. Combinatory effects between AdF35/MK
or AdF35/Sur and Ad5/p53 were examined with CalcuSyn
software (Biosoft, Cambridge, UK). A combination index
(CI) value was calculated based on the cell viability test
with various vp of AdF35/MK or AdF35/Sur and Ad5/p53
(1.25 × 104 vp/cell), and were shown at respective fractions
affected (Fa) points. A CI value equal to 1 denotes an
additive interaction, above 1 antagonism and below 1 syner-
gism. Live cell numbers were calculated with a trypan blue
dye exclusion test.
Western blot analysis
Cell lysate was subjected to sodium dodecyl sulfate poly-
acrylamide gel electrophoresis. The protein was transferredto a nylon filter and was hybridized with Ab against Ad
hexon, 14-3-3σ, glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) (Abcam, Cambrige, UK), Ad E1A (Santa
Cruz Biotech, Santa Cruz, CA, USA), pRb, phosphorylated
pRb, poly (ADP-ribose) polymerase (PARP) (that detected
cleaved PARP), caspase-3, cleaved caspase-3, caspase-8
(that detected cleaved caspase-8), caspase-9 (that detected
cleaved caspase-9), Fas-associated protein with death do-
main (FADD), death receptor 5 (DR5), Bcl-2, Bcl-xL, Bid
(that detected truncated Bid (t-Bid)), phosphorylated p53
at Ser 15 or at Ser 46, Atg5, LC3A/B, Beclin-1, Bax, Puma,
Fas, p21 (Cell Signaling, Danvers, MA, USA), p53 (Lab
Vision, Fremont, CA, USA) or α-tubulin (Thermo
Fisher Scientific, Fremont, CA, USA). The membranes
were developed with the ECL system (GE Healthcare,
Buckinghamshire, UK).
Animal experiments
YES-2 cells (1 × 106) were subcutaneously injected into
BALB/c nu/nu mice and the mice received an intratu-
moral injection of Ad (2.5 × 108 plaque-forming unit
(pfu)/mouse) 4 times. In combinatory experiments, mice
received intratumoral injection of AdF35 (1.875 × 108
pfu/mouse) and/or Ad5 (1.875 × 108 pfu/mouse) when
the tumors reached to about 65 mm3 in volume. Tumor
volumes were calculated according to the formula (1/2 ×
length × width2). The animal experiments with human cell
lines were approved by the animal experiment and welfare
committee at Chiba University (Reference number H26-
242, H26-244). They were performed according to the
guideline on animal experiments and were in compliance
with the Helsinki Declaration.
Virus production
YES-2 cell lysate after Ad infection was examined for
the cytotoxicity with A549 cells and the virus titers were
calculated with the median tissue culture infectious dose
(TCID50) method.
Results
Improved transduction efficacy with AdF35
We compared infectivity of Ad5 and AdF35 vectors to
9 kinds of human esophageal carcinoma cells using
GFP-expressing Ad with flow cytometry (Table 1). The
differential fluorescence intensity of Ad5/GFP and
AdF35/GFP in the same cells was influenced by the Ad
infectivity since the same cytomegalovirus promoter
was used to activate the GFP gene. The esophageal car-
cinoma cells were relatively resistant to Ad5-mediated
transduction compared with HEK293 cells. All the
esophageal cells showed greater infectivity with AdF35/
GFP than with Ad5/GFP in contrast to HEK293 cells
which showed similar transduction with Ad5/GFP and
AdF35/GFP.
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and Ad5
We examined cytotoxic activities of replication-competent
AdF35 and Ad5 on esophageal carcinoma cells, and com-
pared the activities between Ad5/MK and AdF35/MK
(Fig. 1), and Ad5/Sur and AdF35/Sur, with the same cells
(Additional file 1: Figure S1). Susceptibility to replication-
competent Ad was different among the cells tested, but
AdF35 produced greater cytotoxicity than corresponding
Ad5 in some of cells irrespective of the regulatory region.
AdF35/MK achieved cytotoxic effects relatively greater
than Ad5/MK in TE-1, YES-2, YES-5 and T.Tn cells,
whereas the cytotoxicity between the 2 kinds of Ad was
similar in other cells and YES-6 cells were resistant to the
Ad-mediated cytotoxicity. AdF35/Sur also produced
greater cytotoxicity than Ad5/Sur in TE-1, TE-2, TE-10,
YES-2 and T.Tn cells, whereas both types of Ad showed
similar cytotoxicity in other cells. AdF35/LacZ and
Ad5/LacZ did not influence the viability or was minimally
inhibitory at the high Ad doses. These data collectively
suggest that AdF35 held an advantage in the cytotoxicity
over Ad5 in some of the cells such as TE-1, YES-2 and
T.Tn cells.
Cell cycle changes induced by Ad infections
We examined cell cycle distributions caused by AdF35
infections in T.Tn and YES-2 cells (Fig. 2a) (Additional
file 2: Table S1). AdF35/MK- and AdF35/Sur-infectedFig. 1 Enhanced cytotoxicity of AdF35/MK. Viability of esophageal carcinom
Ad5/LacZ or AdF35/LacZ was examined with the WST assay. The relative vi
treatments. Standard errors (SE) bars are shown (n = 3). *P < 0.01; comparing
AdF35/LacZ-infected cellscells initially increased a fraction with more than 4 N
populations (hyperploidy) and subsequently sub-G1 pop-
ulations in a time dependent manner. AdF35/LacZ-in-
fected cells did not show any significant changes in cell
cycle compared with uninfected cells. Uninfected T.Tn
and YES-2 cells showed a small percentage of hyper-
ploidy fractions and AdF35/LacZ infection did not influ-
ence the hyperploid percentages.
Replication-competent Ad activated apoptotic pathways
We further examined molecular events caused by
replication-competent Ad with western blot analyses
(Figs. 2b and 3). Transduction of T.Tn and YES-2 cells
with AdF35/MK or AdF35/Sur but not AdF35/LacZ in-
duced E1A, one of the early viral proteins, and hexon, the
late viral protein (Fig. 2b). Interestingly, expression levels
of pRb and phosphorylated pRb were down-regulated in
T.Tn cells infected with AdF35/MK or AdF35/Sur,
whereas those of phosphorylated pRb in the AdF35/MK-
or AdF35/Sur-infected YES-2 cells were rather up-
regulated. We then examined possible activation of apop-
tosis pathways (Fig. 3a). Transduction with AdF35/MK or
AdF35/Sur but not AdF35/LacZ induced cleavage of
PARP and caspase-3 in both cell lines, demonstrating
replication-competent Ad achieved apoptotic cell death.
Ad-infected T.Tn cells showed cleavage of both caspase-8,
involved in the extrinsic cell death, and caspase-9, in-
volved in the intrinsic mitochondria-mediated cell death,a cells that were treated with various doses of Ad5/MK, AdF35/MK,
ability was calculated based on the absorbance without any
between Ad5/MK- or AdF35/MK-infected cells and Ad5/LacZ- or
Fig. 2 Cell cycle changes and expressed viral proteins of replication-competent Ad. T.Tn cells and YES-2 cells were uninfected or infected with
AdF35/LacZ, AdF35/MK or AdF35/Sur (1 × 104 vp/cell), and cultured for the indicated time. a Representative flow cytometrical analyses about cell
cycle changes in YES-2 (day 3) and T.Tn cells (day 4). b Expression levels of viral proteins and pRb examined with western blot analyses. GAPDH
was used as a loading control
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caspase-9 but not casepase-8. Minimal changes of t-Bid
were detected only in YES-2 cells. We also examined ex-
pression levels of molecules in an upstream pathway of
the extrinsic apoptosis and found that expression levels of
FADD and DR5, one of the tumor necrosis factor-related
apoptosis-inducing ligand receptors, remained unchanged
in YES-2 cells, but DR5 slightly increased in T.Tn cells.
Moreover, we found that Bcl-2 and Bcl-xL expression
was down-regulated in Ad-infected YES-2 cells, whereas
up-regulated Bcl-2 with down-regulated Bcl-xL was de-
tected in Ad-infected T.Tn cells. The differential regula-
tions between Bcl-2 and Bck-xL could be due to ability tohold a balance between apoptosis and anti-apoptosis in
T.Tn cells. These data thereby demonstrated that both
the intrinsic and the extrinsic pathways were activated
in T.Tn cells, whereas the intrinsic apoptosis was pref-
erentially induced in YES-2 cells. We further investi-
gated expression levels of Atg5, Beclin-1, and LC3A/B I
and II, which were linked with the autophagy pathway
(Fig. 3b). These levels were scarcely influenced by
AdF35/MK or AdF35/Sur except slight increase of
LC3A/B II in YES-2 cells. These data suggested that
AdF35/MK and AdF35/Sur induced caspase-mediated
apoptotic pathways with a cell type-dependent involve-
ment of the extrinsic pathway, and that autophagy
Fig. 3 Replication-competent Ad-induced activation of apoptosis pathways. T.Tn cells and YES-2 cells were uninfected or infected with AdF35/LacZ,
AdF35/MK or AdF35/Sur (1 × 104 vp/cell), and cultured for the indicated time. a Expression levels of apoptosis- and b autophagy-linked proteins were
examined with western blot analyses. GAPDH was used as a loading control
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cytotoxicity.
Replication-competent Ad produced anti-tumor effects
in vivo
We investigated the anti-tumor effects of replication-
competent Ad in an animal model (Additional file 3:
Figure S2). Nude mice bearing subcutaneous YES-2 tu-
mors were treated with intratumoral injections of AdF35/
MK, AdF35/Sur or AdF35/LacZ as a control. Administra-
tion of AdF35/MK and AdF35/Sur but not AdF35/LacZ
retarded the subsequent tumor growth.Combinatory effects of replication-competent AdF35
and Ad5/p53
We examined possible combinatory effects between
AdF35/MK or AdF35/Sur and Ad5/p53 (Fig. 4). Both
YES-2 and T.Tn cells had mutated p53 genes and were
susceptible to Ad5/p53-mediated cytotoxicity [17]. These
cells were infected with different amounts of replication-
competent AdF35 or Ad5/p53, or in combination with
AdF35 and Ad5/p53. The combinatory treatments with
AdF35/MK and Ad5/p53 produced greater cytotoxicity
than individual Ad alone in both cells (Fig. 4a). The CI
values at Fa points between 0.3 and 0.8 in T.Tn cells or
Fig. 4 Combinatory cytotoxicity of replication-competent Ad and Ad5/p53. a Cells were infected with AdF35/MK, Ad5/p53, or AdF35/MK (at indicated
doses) plus Ad5/p53 (1.25x104 vp/cell). Relative viability of cells was examined with the WST assay and SE bars are shown (n = 3). CI values in
the combination of AdF35/MK and Ad5/p53 in respective Fa points were shown. b Cells were infected with AdF35/Sur, Ad5/p53, or AdF35/Sur plus
Ad5/p53 (1.25x104 vp/cell). Relative viability of cells was examined with the WST assay and SE bars are shown (n = 3). CI values in the combination of
AdF35/Sur and Ad5/p53 in respective Fa points were shown. CI < 1, CI = 1 and CI > 1 indicate synergistic, additive and antagonistic actions, respectively.
*P < 0.01; comparing between (A) AdF35/MK + Ad5/p53- or (B) AdF35/Sur + Ad5/p53-infected cells and (A) AdF35/MK-, Ad5/p53-, (B) AdF35/Sur- or
Ad5/p53-infected cells
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produced synergistic effects. Transduction with Ad5/p53
also enhanced AdF35/Sur-induced anti-tumor effects in
both cells and the CI values at the same Fa ranges showed
synergism in the cytotoxicity between AdF35/Sur and
Ad5/p53 (Fig. 4b).Growth inhibition by replication-competent AdF35 and
Ad5/p53
We also investigated combinatory effects of replication-
competent AdF35 and Ad5/p53 on cell proliferation
(Table 2). YES-2 cells were infected with replication-
competent AdF35 and with Ad5/p53 or Ad5/LacZ, and
Table 2 Combinatory effects of AdF35/MK or AdF35/Sur and
Ad5/p53 on cell growth
Treatment Time (day) Cell numbers (×104)
(-) 2 174.3 ± 4.4
Ad5/LacZ 2 185.9 ± 2.4
Ad5/p53 2 98.3 ± 4.1b
AdF35/MK 2 133.7 ± 6.1a
AdF35/MK + Ad5/LacZ 2 141.9 ± 7.1
AdF35/MK + Ad5/p53 2 28.0 ± 2.1d
AdF35/Sur 2 147.7 ± 1.2a
AdF35/Sur + Ad5/LacZ 2 146.3 ± 1.8
AdF35/Sur + Ad5/p53 2 24.3 ± 3.0d
(-) 4 747.3 ± 5.1
Ad5/LacZ 4 718.2 ± 10.0
Ad5/p53 4 57.7 ± 5.6b
AdF35/MK 4 67.7 ± 7.0b
AdF35/MK + Ad5/LacZ 4 72.2 ± 1.5
AdF35/MK + Ad5/p53 4 3.3 ± 0.3d
AdF35/Sur 4 160.0 ± 3.0b
AdF35/Sur + Ad5/LacZ 4 134.9 ± 1.2
AdF35/Sur + Ad5/p53 4 19.3 ± 2.3d
(-) 6 1717.7 ± 1.3
Ad5/LacZ 6 1838.6 ± 7.2
Ad5/p53 6 1.2 ± 0.4b
AdF35/MK 6 12.0 ± 0.6b
AdF35/MK + Ad5/LacZ 6 20.3 ± 0.3
AdF35/MK + Ad5/p53 6 0 ± 0c
AdF35/Sur 6 40.3 ± 1.3b
AdF35/Sur + Ad5/LacZ 6 87.0 ± 3.8
AdF35/Sur + Ad5/p53 6 0 ± 0c
YES-2 cells were uninfected or infected with Ad as indicated (AdF35/MK and
AdF35/Sur: 1.2× 103 vp/cell; Ad5/p53 and Ad5/LacZ: 6.5× 103 vp/cell). Live cell
numbers were determined with a trypan blue dye exclusion test. Mean
percentages with SEs are shown (n = 3)
aP < 0. 05, bP < 0. 01; comparing between Ad/p53-, AdF35/MK- or AdF35/
Sur-infected cells, and uninfected or Ad5/LacZ-infected cells. cP < 0. 05,
dP < 0. 01; comparing between AdF35/MK + Ad5/p53- or AdF35/Sur + Ad5/
p53-infected cells, and AdF35/MK-, AdF35/Sur-, Ad5/p53-, AdF35/MK + Ad5/
LacZ-infected or AdF35/Sur + Ad5/LacZ-infected cells
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AdF35/MK or Ad5F35/Sur and Ad5/p53 inhibited cell
proliferation greater than AdF35/MK, AdF35/Sur or
Ad5/p53 alone. We then examined cell cycle changes
after the combinatory treatments with AdF35/MK and
Ad5/p53 (Fig. 5a) (Additional file 4: Table S2). Infection
with Ad5/p53 slightly increased G0/G1 and sub-G1
fractions in YES-2 cells, and AdF35/MK infection re-
sulted in induction of hyperploidy populations. In con-
trast, transduction with both AdF35/MK and Ad5/p53
rather decreased hyperploidy fractions and greatlyincreased sub-G1 populations, suggesting that the com-
bination augmented apoptotic cell death.
In vivo anti-tumor effects by AdF35/MK and Ad5/p53
We investigated the anti-tumor effects produced by
Ad5F35/MK and Ad5/p53 in an animal model (Fig. 5b).
Nude mice injected with YES-2 cells were treated with
intratumoral administrations of Ad5F35/MK and/or Ad5/
p53. Tumor growth of mice treated with AdF35/MK and
Ad5/p53 was retarded compared with that of mice
injected with either AdF35/MK or Ad5/p53 alone. In con-
trast, Ad5/LacZ treatments did not produce any combin-
atory effects with AdF35/MK although AdF35/LacZ alone
slightly inhibited the tumor growth compared with Ad5/
LacZ injections.
Mechanisms of combinatory effects
We examined whether the enhanced anti-tumor effects
of replication-competent AdF35 by Ad5/p53 infection
were associated with increased production of the viral
progenies. YES-2 cells were infected with AdF35/MK or
AF35/Sur and Ad5/p53, and the cell lysate was tested
for the viral amounts produced (Fig. 5c). Ad5/p53 infec-
tion significantly suppressed propagation of AdF35/MK
or AdF35/Sur. The enhanced apoptosis by co-infected
Ad5/p53 was not thereby due to increased production of
infectious Ad progenies, but could be linked with aug-
mented p53 functions. We then examined p53 activation
processes with western blot analyses (Fig. 5d). Transduc-
tion of YES-2 cells with Ad5/p53 increased p53 expres-
sion levels and the phosphorylation at Ser 15 residues,
whereas AdF35/MK infection did not augment the p53
and the phosphorylation. In contrast, a combinatory use
of AdF35/MK and Ad5/p53 up-regulated p53 phosphor-
ylation both at Ser 15 and Ser 46 residues, activation
markers of the p53 pathways. Ad5/LacZ did not modu-
late endogenous p53 expression levels or induce the
phosphorylation. We further examined the p53 down-
stream pathways. Ad/p53 infection induced expression
of Bax, Fas, p21 and 14-3-3σ, and AdF35/MK infection
stimulated expression of Bax and 14-3-3σ. The combin-
ation of both Ad further augmented expression levels of
Bax, Fas, p21 and 14-3-3σ, and induced Puma expres-
sion. These data showed that AdF35/MK activated Ad5/
p53-mediated p53 pathways.
Discussion
In this study, we demonstrated that replication-competent
AdF35 regulated by an exogenous transcriptional regula-
tory region induced apoptotic cell death in esophageal car-
cinoma and that combination of the AdF35 and Ad5/p53
produced synergistic cytotoxicity through enhanced acti-
vation of the p53 pathways. A direct injection of 2 kinds of
Ad vectors into esophageal carcinoma is technically
Fig. 5 Production of anti-tumor effects with replication-competent Ad and Ad5/p53. a Representative flow cytometrical analyses about cell cycle
changes. YES-2 cells were uninfected or infected with AdF35/MK (1.2 × 103 vp/cell), Ad5/p53, Ad5/LacZ (6.5 × 103 vp/cell) or in combination, and
were analyzed on day 2. b Anti-tumor effects in vivo produced by AdF35/MK and Ad5/p53. Nude mice that were subcutaneously injected with
YES-2 cells (1x106) were treated with Ad as indicated (1.875x108 pfu/mouse) on day 0, 3, 6 and 9 after the tumors developed to 65 mm3 (n = 5).
The tumor sizes were measured every 4 days. Means and SE bars are shown. *P < 0.01. c Influence of Ad/p53 on viral proliferation of replication-
competent AdF35. YES-2 cells were infected with AdF35/MK or AdF35/Sur, or in combination of AdF35/MK or AdF35/Sur and Ad5/p53 or Ad5/LacZ
(AdF35/MK and AdF35/Sur: 1.2 × 103 vp/cell; Ad5/p53 and Ad5/LacZ: 6.5 × 103 vp/cell), and the cell lysate was extracted on day 3 or 4. The viral titers
were assayed with TCID50 method with A549 cells. Means and SE bars are shown (n = 3).
*P < 0.05. d Activation of the Ad5/p53-derived p53 pathways
with AdF35/MK. YES-2 cells were uninfected or infected with AdF35/MK (1.2 × 103 vp/cell), Ad5/p53 or Ad5/LacZ (6.5 × 103 vp/cell) as a control, or in
combination of AdF35/MK and Ad5/p53 or Ad5/LacZ for 2 or 3 days. Expression levels of molecules in the p53 pathways were analyzed with western
blot analyses and those of α-tubulin were used as a loading control
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binatory Ad usage can also contribute to enhanced sensi-
tivity to chemotherapeutic agents and radiotherapy.
Fiber-modified AdF35 targeting CD46 molecules have
advantages. One is high infectivity of AdF35 to human tu-
mors since CD46 expression levels are maintained in tu-
mors in contrast to CAR which is often down-regulated in
the expression [18]. Another is to transduce cells which
are infected with Ad5 vectors and consequently to enablesimultaneous dual gene transfer. We took an advantage of
the mutually uninhibited infection with AdF35 and Ad5
vectors and examined possible combinatory cytotoxicity.
Ubiquitous distributions of CD46 molecules among
normal tissues however need an additional system to
secure tumor specificity in AdF35-mediated transduc-
tion. The transcriptional regulatory regions of the MK
and the Sur can activate an exogenous gene with tumor
selectivity and we previously demonstrated preferential
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when the E1A gene was activated by MK or Sur promoter
region [11–14]. The promoter regions were active in
esophageal carcinoma (Additional file 5: Table S3), but the
transcriptional activity may not be directly linked with the
Ad-mediated cytotoxicity since multiple factors such as
sensitivity to cell death are involved in the cytotoxicity.
Our previous pathological analyses also showed massive
necrosis and pyknotic changes in Ad-injected tumors but
the injected non-tumorous regions remained unchanged
[14]. On the other hand, regulation of pRb phosphoryl-
ation was complex in Ad-infected cells. YES-2 cells
showed hyper-phosphorylated pRb, which could favor
viral replications through enhanced cell cycle progression.
In contrast, hypo-phosphorylation of pRb in T.Tn cells ra-
ther suggested cell cycle arrest prior to cell death. These
phosphorylation statuses however did not accord with the
actual cell cycle data in Additional file 2: Table S1 and fur-
ther investigations are required as for pRb regulation in
Ad replications and subsequent cell death.
Combinatory effects of replication-competent Ad and
forced expression of p53 can be examined either with dual
transduction using 2 kinds of Ad vectors or with a single
vector system in which the p53 gene was integrated into
the replication-competent Ad vector. Different groups
using a dual transduction system demonstrated that com-
binatory cytotoxicity was achieved with replication-
incompetent Ad5/p53 and either with wild-type Ad5 [19]
or replication-competent Ad5 that were activated by tel-
omerase reverse transcriptase (TERT) promoter [20].
These studies however used the same type of Ad5 vectors
in dual transduction and did not consider possibility of de-
creased infectivity. Moreover, previous studies with a
replication-competent Ad5 vector which had the wild-
type p53 gene and was activated by Sur [21] or TERT pro-
moter [22, 23] demonstrated greater cytotoxicity than
Ad5/p53 or the promoter-activated Ad5 alone. These pre-
vious studies however did not analyze the combinatory ef-
fects in contrast to the present study that demonstrated
the synergism. The p53-bearing single vector system in
the previous study also showed that production of viral
progenies was uninhibited by the expressed p53 and sug-
gested that infection-induced down-regulated p21 and
Mdm-2 were associated with Ad-mediated apoptosis and
autophagy [22, 23]. In contrast, the present study demon-
strated that production of AdF35/MK or AdF35/Sur pro-
genies was rather inhibited by co-transduced p53, which
was probably linked with p53-mediated decrease of cell
growth and acceleration of cell death.
Cell death mechanisms mediated by replication-
competent Ad are complex. The present study showed
that the cytotoxicity was not attributable to autophagy
but to apoptosis although activation of the intrinsic and/or
the extrinsic apoptotic pathways was dependent on cellstypes tested. Yamasaki et al. showed that OBP-702, p53-
expressing and TERT promoter-activated replication-
competent Ad induced apoptosis in lung and esophageal
carcinoma cells [22], but Hasei et al. demonstrated with
the same OBP-702 killed osteosarcoma cells through au-
tophagy [23]. These previous studies thus indicated differ-
ential cell death mechanisms even with the same Ad
construct. Cell death due to Ad replication was influenced
by balance between pro-apoptotic and anti-apoptotic sig-
naling, and was partly linked with Ad-derived E1B-19 kDa
molecules [24]. Recent studies also demonstrated that an
elevated caspase activity in the extrinsic pathway contrib-
uted to Ad-induced autophagy-mediated cell death [25].
These reports together with the present data suggest that
Ad replication-mediated cell death is controlled by mul-
tiple factors including genetic differences of the infected
cells, which is resulted in varied levels of susceptibility to
apoptosis and autophagy. Our preliminary study with
an inhibitor for necrosis suggested that necrosis was
not involved in Ad replication-induced cell death, but
further investigation is required to clarify the involve-
ment of necrotic cell death.
We demonstrated that phosphorylation of Ad-induced
p53 was augmented by co-infected replication-competent
AdF35 although the AdF35 themselves did not induce
phosphorylation of endogenous p53. A possible upstream
pathway to phosphorylate p53 remains uncharacterized,
but Ad proteins synthesized during the replications such
as Ad E1B-55 kDa and E4-ORF3 may regulate p53 expres-
sion at various levels even in an epigenetic manner [26].
Regulation of the p53 pathways after Ad infection is con-
trolled even by a host defense system such as interferons
[27]. A biomarker to predict the efficacy of Ad-mediated
cytotoxicity to target tumors as well as detection of Ad
ability to penetrate into tumors is preferable in the case of
its clinical application. Ad infectivity can be one of the fac-
tors involved in the cytotoxicity but is not completely
dependent on the receptor expression levels because an
auxiliary receptor play a role in Ad infection and the
threshold level necessary for the infection can be different
among the target cells [18]. It is crucial to examine a pos-
sible correlation between the infectivity and anti-tumor ef-
fects with clinical specimens. Our different results showed
that an Ad5 injection into subcutaneous tumors did not
affect the subsequent gain of mice body weight but only
elevated transaminases with a mild degree, suggesting the
feasibility of a clinical trial.
We noticed that replication-competent AdF35 induced
hyperploid populations which preceded increase of sub-
G1 fractions. Cherubini et al. showed that replication-
competent Ad with deletion of E1B-55 kDa molecules
induced hyperploidy populations in normal cells, and
suggested a possible linkage between the hyperploidy
and increase expression of mitotic arrest-deficient 2
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checkpoint [29]. The study also indicated that wild-type
Ad5 did not induce the hyperploidy and subsequently
ruled out a possibility that the hyperploidy was caused
by amplified viral DNA contents [28]. Our previous
study also found the E1B-55 kDa-defective Ad induced
similar hyperploidy in mesothelioma cells without any
changes at the chromosome levels [30]. Our preliminary
data also showed that the wild-type Ad minimally in-
duced hyperploidy but rapidly increased sub-G1 frac-
tions in esophageal carcinoma (data not shown). These
data suggest that Ad replication processes per se are not
directly associated with hyperploidy, but that differential
cell death mechanisms, which are influenced by a num-
ber of genetic difference in infected cells, may also play
a role in the aberrant cell cycle progression. Investiga-
tions on genesis of the hyperploidy require genetically
modified cells to standardize the genetic backgrounds.
Conclusions
Esophageal carcinoma can be an ideal target for gene ther-
apy. Several studies demonstrated the clinical feasibility
[31, 32] and our previous clinical study with Ad5/p53
showed that direct administration of Ad produced none
of the major adverse effects [33]. We demonstrated that
combination of replication-incompetent Ad5/p53 and
replication-competent AdF35 achieved synergistic cyto-
toxicity through activated the p53 pathways although
replication of AdF35 itself was suppressed. The present
study suggests that administration of the dual vectors
at an optimized ratio, perhaps being personalized for
the p53 expression in an individual tumor, can broaden
therapeutic options for esophageal carcinoma, which
includes further combination with chemotherapy and
radiotherapy.
Additional files
Additional file 1: Figure S1. Enhanced cytotoxicity of AdF35/Sur.
Viability of esophageal carcinoma cells that were treated with various
dose of Ad5/Sur, AdF35/Sur, Ad5/LacZ or AdF35/LacZ was examined
with the WST assay. The relative viability was calculated based on the
absorbance without any treatments. SE bars are shown (n = 3). *P < 0.01;
comparing between Ad5/Sur- or AdF35/Sur-infected cells and Ad5/LacZ- or
AdF35/LacZ-infected cells.
Additional file 2: Table S1. Cell cycle distribution after AdF35
infections.
Additional file 3: Figure S2. Anti-tumor effects in vivo produced by
AdF35/MK or AdF35/Sur. Nude nice that were subcutaneously injected with
YES-2 cells (1x106) were treated on day 7, 10, 13 and 16 with intra-tumoral
injection of AdF35/LacZ, AdF35/MK or AdF35/Sur (2.5x108 pfu/mouse), or
with phosphate buffered-saline (PBS) as a control. The tumor sizes were
measured every 4 days. Means and SE bars are shown. *P < 0.01.
Additional file 4: Table S2. Cell cycle distribution after combinatory
Ad infections.
Additional file 5: Table S3. Transcriptional activity of MK and Sur
regulatory regions.Abbreviations
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